Kornimate/medical-research-clean huggingface dataset:
treatment of acute asthma in er with combination of systemic steroids and inhaled steroids

Conditions: Asthma Exacerbation

Summary: we assume that the combination of systemic steroids and inhaled steroid in the first hour of treatment in the er will decrease the admission rate and improve faster the pulmonary function. 120 patients refferd to the er due to asthma attack aged 18-60 with pfr \< 60% 0o predicted will participate in the study after giving informed consent. the usual treatment in the er is inhalation of beta 2 short acting and i.v solumedrol 120 mg . the study group will recieve in addition 3 inhalation of budesonide 1000 microgram each during the first hour. the controlled group will recieve nacl 0.9% pfr will be followed 0 30 60 120 min.

primary end points- pft improvment and admission rate.

Eligibility criteria:
inclusion criteria: * asthmatic patients aged 18-60 with pfr \< 60% of predicted exclusion criteria: * patients with other chronic diseases * cardiac renal hepatic etc will be excluded

Keywords: dyspnea cough
pre-oxygenation with facemask oxygen vs high-flow nasal oxygen vs high-flow nasal oxygen plus mouthpiece oxygen

Conditions: Apnea; Respiration; Arrest; Anesthesia

Summary: pre-oxygenation increases oxygen reserves in the body to reduce the likelihood of oxygen desaturation on induction of general anaesthesia. pre-oxygenation with facemask is the commonest method method of pre-oxygenation. high-flow nasal oxygen is a newer alternative. this study randomises participants to receive pre-oxygenation by one of three methods: facemask, high-flow nasal oxygen, high-flow nasal oxygen plus mouthpiece.

the administration of supplemental oxygen prior to induction of anaesthesia is known as pre-oxygenation. pre-oxygenation increases oxygen reserves in the body with the purpose of delaying the time until oxygen desaturation after breathing stops (apnoea) following the administration of an anaesthetic. in the last decade, clinicians have begun utilising high-flow nasal oxygen for pre-oxygenation. however, the rationale for this is based largely on its ability to achieve ongoing oxygenation after the onset of apnoea (apnoeic oxygenation). this study isolates oxygen administration with high-flow nasal oxygen to the period when the person is breathing, without ongoing oxygen administration during the apnoea period, to quantify its effects during the pre-oxygenation period only. a third group of participants breathes oxygen through a mouthpiece in addition to receiving oxygen via high-flow nasal cannulae. the effect of these pre-oxygenation methods will be measured by the time taken until oxygen saturation levels decline to the lower end of the normal range (92%), along with other parameters such as blood oxygen levels.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * asa 1 or 2 * receiving a general anaesthetic for non-emergent surgery exclusion criteria: * asa score ≥3 * bmi ≥ 30 kg/m2 * nasal obstruction * baseline spo2 ≤95% on room air * anticipated difficult airway management * requirement for awake intubation * pregnancy * positive pcr test for coronavirus.
fascia iliaca compartment block and ipack block in total knee arthroplasty

Conditions: Arthropathy of Knee; Analgesia

Summary: the investigators sought to compare the effectiveness of postoperative pain control between the standard intravenous multimodal analgesia procedure used in managing patients undergoing total knee surgery, who experience severe postoperative analgesia needs, and multimodal analgesia procedures that incorporate ultrasound-guided peripheral nerve blocks (fascia iliaca compartment block or ipack block) during postoperative follow-up. the aim is to determine which procedure is more effective.

all patients who received a total knee replacement surgery conducted by orthopaedic surgeons at the operating theatre of health sciences university ankara atatürk sanatorium training and research hospital and underwent postoperative pain assessment by anaesthetists will be retrospectively reviewed as part of the study. postoperative pain management follow-up for patients who have undergone surgical procedures at anaesthesiology and reanimation clinic is standard practice during patients hospitalization. patients who have undergone painful and significant surgical procedures are typically given postoperative patient-controlled analgesia devices and are administered intravenous painkillers that are under the patient's control. as part of multimodal analgesia procedure, the investigators apply peripheral nerve blocks routinely to eligible patients, provided that the necessary criteria are met. once the postoperative anesthesiology and reanimation clinic's follow-up form, the regional anaesthesia follow-up form, is completed, patients receive coordinated follow-up care from anaesthesiologists and surgical physicians in postoperative ward to monitor analgesic requirements and increase patient satisfaction. hourly monitoring ensures that patients receive optimal care. the aims of study to examine the effectiveness of these procedures. the investigators will include all patients who received elective total knee arthroplasty surgery in the operating room of ankara atatürk sanatorium training and research hospital within the past year (between 01 march 2022 and 31 march 2023) in retrospective file review and postoperative pain follow-up study.

Eligibility criteria:
inclusion criteria: * patients who have undergone elective total knee surgery * asa i-iii patients exclusion criteria: * those \<30 kg * people under 18 years of age * patients with missing follow-up forms * patients with a history of chronic opioid or corticosteroid use * patients with a history of inflammatory gonathrosis * patients with synovectomy operation history

Keywords: total knee arthroplasty ipack block fascia iliaca compartment block postoperative pain peripheral nerve block
investigation of safety and efficacy of sb injection in patients with advanced and metastatic non-small cell lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: the purpose of this study is to determine efficacy of sb injection in non small cell lung cancer.

all eligible patients will receive sb injection therapy for 4 cycles (14\~21 days for each cycle). sb injection treatment could be continue after completion of therapy cycles until 6th cycle. it depends on the investigator's decision and patient's will. efficacy will be evaluated every two cycles.

Eligibility criteria:
inclusion criteria: * age of 18-70 years * patients with histologically or cytologically confirmed non-small cell lung cancer * patients who had failed more than 1 cycle of standard therapy with advanced or metasatic stage not available to any of resectable surgery or radiotherapy. * patients with measurable lesions * eatern cooperative oncolgy group status 0 to 2. * life expectancy \>/= 5 months * patients with adequate organ(heart, kidney, liver)and bone marrow function, as defined by 1. absolute neutrophil count \>/= 1.5 x 10\^9/l, platelet count \>/= 100 x 10\^9/l 2. total bilirubin \</= upper limit of normal 3. aspartate aminotransferase and/or alanine aminotransferase \</= 2 x upeer limit of normal 4. creatinine \</= 1.5 x upeer limit of normal * patients who have signed the informed consent form. exclusion criteria: * female volunteers admitted to the study must be using a reliable means of contraception * received radiation therapy within 6 weeks before randomization * known brain or spinal cord metastases * have acute infection * have active infection or serious concomitant systemic disorder incompatible with the study * presence or history of malignancy other than non-small cell lung cancer * have severe neurologic or psychological disorder * patients who have to receive other chemo-radiotherapy or immunotherapy * patients who have received chemotherapy within the previous 30 days * patients who are candidates for combined modality treatment. * patients who have participated in a clinical study within the previous 30 days
a randomized trial of pf-00299804 taken orally versus erlotinib taken orally for treatment of advanced non-small cell lung cancer that has progressed after one or two prior chemotherapy regimen

Conditions: Non-small Cell Lung Cancer

Summary: this study will compare pf-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one of these drugs, and followed for efficacy and tolerance of each.


Eligibility criteria:
inclusion criteria: * advanced measurable non-small cell lung cancer (nsclc); * progressed after 1-2 prior chemotherapy; * eastern cooperative oncology group (ecog) 0-2; * tissue available for future kras/ egfr testing exclusion criteria: * prior epidermal growth factor receptor (egfr) targeted therapy; * active or untreated central nervous system (cns) metastases;

Keywords: lung cancer advanced second or third line
a study of ly900014 in participants with type 1 diabetes

Conditions: Type 1 Diabetes Mellitus

Summary: the main purpose of this study is to evaluate the efficacy of the study drug ly900014 compared to insulin lispro, both in combination with insulin glargine or insulin degludec, in adults with type 1 diabetes (t1d).


Eligibility criteria:
inclusion criteria: * have t1d for at least 1 year prior to screening and continuously using insulin for at least 1 year. * hba1c of ≥7.0 and ≤9.5%. * use insulin lispro, insulin aspart, or insulin glulisine as prandial insulin. * use insulin glargine, insulin detemir, insulin degludec, or neutral protamine hagedorn (nph) insulin as basal insulin. exclusion criteria: * have used other antihyperglycemic medications or therapies (inhaled, oral or injectable) within 90-days of screening. * have had more than 1 severe hypoglycemic episode within 6 months of screening. * have had more than 1 hospitalization related to hyperglycemia or diabetic ketoacidosis within 6 months of screening. * have clinically significant gastrointestinal disease.
effect of intercessory prayer in patients with breast cancer in radiotherapy treatment: clinical trial

Conditions: Breast Cancer

Summary: living with breast cancer and forms of treatment, among them radiation therapy can cause both side effects such as pain, fatigue and skin changes that affect the well-being, as anxiety, feelings of isolation and changes in routine, which generate existential conflicts and allow the origin of the spiritual anguish phenomenon, which in turn, aggravates the physical and emotional symptoms and the ability to fight the disease. thus, this study aims to evaluate the effect of intercessory prayer on levels of spiritual distress, religious / spiritual coping, psychological morbidity (anxiety and depression) and amylase levels salivary present in patients with breast cancer radiotherapy.

reflection on the existence and the meaning of life, common among people with breast cancer radiotherapy generates a suffering that, when directed to the spiritual dimension, results in spiritual distress. in addition, combined with the presence of this phenomenon can flourish during this phase psychological morbidity such as anxiety and depression. in order to face this situation, each person uses cognitive and behavioral strategy according to their beliefs and their meaning of life (religious / spiritual coping). the use of intercessory prayer, where an individual asks a higher being for the benefit of someone seen as receiver, is a strategy that can help people cope with the situation of illness and restore your health. prayer is one of these activities in the nursing intervention "spiritual support" (5420) proposed by the nursing interventions classification (nic). a complementary alternative therapy is considered and can be used as an adjuvant in radiotherapy. therefore, the aim of this study is to verify that the intercession of prayer cause positive effects on levels of spiritual distress, religious coping / spiritual and psychological morbidity (anxiety and depression) present in patients with breast cancer radiotherapy. thus, a clinical trial will be used randomized controlled and mascaraed. intervention group will receive the prayer of intercession and control groups (positive and negative) usual care. the data will be analyzed using the statistical package for the social sciences version 20.0 and will be adopted as the reference value p \<0.05.

Eligibility criteria:
inclusion criteria: * individuals diagnosed with breast cancer in adjuvant and neoadjuvant radiotherapy treatment; * both female and male participants are being studiedolder; * minimum age of participants is 18 years. exclusion criteria: * not being with consciousness, memory and orientation preserved; * patients with clinical conditions that affect the continuity in the study or express request not to continue participating in the study.

Keywords: nursing intercessory prayer spirituality clinical trials
dapagliflozin dppiv inhibitor add-on study

Conditions: Type 2 Diabetes

Summary: this study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to existing treatments (sitagliptin alone or in combination with metformin). the effect of dapagliflozin on weight and blood pressure will also be studied.


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes * patients who are not receiving treatment , or those who currently receive metformin, sitagliptin or vildagliptin or the combination of these * patients will be screened by a blood test and only those who need additional therapy can be enrolled exclusion criteria: * patients with type 1 diabetes * patients with very poorly controlled diabetes * any clinically significant illness, which in the judgement of the investigator would compromise the patient's safety or successful participation in the clinical study

Keywords: dapagliflozin dpp iv inhibitor add on study inadequate control
a phase 4 study with tamsulosin ocas to assess nighttime voiding.

Conditions: Benign Prostatic Hyperplasia

Summary: randomized, double-blind, placebo-controlled study with two treatment arms (tamsulosin ocas 0.4 mg \& placebo). the study comprises a 2-week placebo run-in followed by a 12-week treatment period.


Eligibility criteria:
inclusion criteria: * diagnosed as having luts associated with bph * on average, at least 2 voids per night over the last week * a maximum of 4 hours of undisturbed sleep expected per night (night time is defined as the time from going to bed with the purpose of sleeping until waking up with the purpose of getting up) exclusion criteria: * subject is currently taking diuretics * subjects who work shift hours and whose hours of work include any time between 23.00 and 06.00h

Keywords: benign prostatic hyperplasia nocturia actigraphy tamsulosin
robotic rehabilitation treatment of stroke patients

Conditions: Stroke, Acute; Stroke, Ischemic

Summary: storke results in severe deterioration in quality of life and exercise. severe disorders need to be treated as soon as possible and they need to be rehabilitated quickly in order for motor functions to develop properly. in the acute / subacute phase, patients are given robotic treatment. in addition to the study of mtoros functions, the study of gait and codination is the primary result. patients treated with soft exoskeleton receive 15 treatments and movement testing is performed continuously. members of the control group receive standard rehabilitation therapy. after 3 weeks, both groups will participate in a control study and then in a repeat control study at week 6. our main goal is to compare the results and determine the efficiency of the robotic device.


Eligibility criteria:
inclusion criteria: post stroke 6mwt : 120\> minimum after stroke 3 days exclusion criteria: sever heart problem sever demeanor alcoholism drug problems

Keywords: balance soft exoskeleton walk robotic
embolization for meningioma

Conditions: Meningioma

Summary: the natural course for meningioma suggests that a majority will grow over time. treatment is usually indicated in growing or symptomatic meningiomas. surgery is usually primary treatment, but there is a significant risk of adverse effects. stereotactic radiotherapy is most often reserved to treat relapses after surgery, and except for surgery and radiotherapy there are no other established treatment methods. endovascular embolization may be used in selected cases as a preoperative adjunct to reduce intraoperative bleeding. there is a need for more treatment options in patients with meningioma, both in uncomplicated, asymptomatic cases and in more complex cases. the aim of this study is to assess radiological and clinical results of therapeutic endovascular embolization for meningioma


Eligibility criteria:
inclusion criteria: * radiological diagnose of typical intracranial meningioma (homogenous contrast enhancement or dural attachment) * indication for treatment due to growth, symptoms or both * tumor location suggestive of vascular supply via middle meningeal artery branches * age 18 years or older * karnofsky performance status of 90 or better (able to carry on normal activity and work) exclusion criteria: * informed consent not possible (e.g. language barriers, aphasia, cognitive impaired) * previously treated for meningioma * intraosseous growth * tumor related brain edema * neurofibromatosis type 2 * systemic cancer * epilepsy * progressive neurodegenerative disorder (eg. ms, parkinsons disease) * history of psychiatric disorder * unfit for participation for any other reason judged by the physician including patients * contraindications to mri * allergic to contrast agents * relative contraindications to endovascular treatment judged from ct angiography (tortoise carotid arteries, carotid stenosis, calcified aortic arch, anatomical vascular variants/anomalies suggesting increased risk with endovascular treatment) * dsa (digital subtraction angiography) from carotid artery suggesting that significant vascular supply is from other vessels than the mma.

Keywords: brain neoplasms therapeutics
randomized trial with vinorelbine and gemcitabine versus docetaxel and gemcitabine in patients with non-small cell lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: the purpose of this study is to evaluate whether the gemcitabine/vinorelbine combination versus the gemcitabine/docetaxel combination as first line treatment, offers a survival advantage in patients with locally advanced/metastatic nsclc.

cisplatin-based chemotherapy represented the backbone of treatment of advanced nsclc. however, several trials comparing platinum versus non-platinum based chemotherapy regimens failed to demonstrate a statistically significant difference in terms of time to tumor progression or survival. newer agents such as gemcitabine, docetaxel and vinorelbine have shown significant activity in the treatment of nsclc. gemcitabine/vinorelbine combination as first line treatment has demonstrated a response rate (rr) of 18-43% and a median overall survival (os) of 9.8-13 months. similarly, the gemcitabine/docetaxel combination has shown a rr 32-35% and a median os of 9-12 months. given their proven efficacy, the combination of these two doublets, would be interesting.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed, unresectable locally advanced (stage iiib with pleural effusion) and/or metastatic (stage iv) nsclc * no previous therapy for advanced/metastatic nsclc is allowed * age \> 18 years * bidimensionally measurable disease * performance status (who) 0-2 * adequate liver (serum bilirubin \< 1.5 times the upper normal limit (unl); ast and alt \< 2.5 times the unl in the absence of demonstrable liver metastases, or \< 5 times the unl in the presence of liver metastases); adequate renal function (serum creatinine \< 1.5 times the unl); and bone marrow (neutrophils ≥ 1.5x 109 /l, and platelets ≥ 100x 109 /l) function * previous radiotherapy, either in the adjuvant setting or for the treatment of metastatic disease is allowed provided that the measurable lesions are outside the radiation fields * life expectancy of more than 3 months * patient able to take oral medication * at least 4 weeks since prior radiotherapy * written informed consent exclusion criteria: * active infection * history of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias) * malnutrition (loss of ≥ 20% of the original body weight) * performance status: 3-4 * sensor or motor neuropathy \> grade i * second primary malignancy, except for non-melanoma skin cancer * psychiatric illness or social situation that would preclude study compliance * pregnant or lactating women * known, symptomatic central nervous system metastases

Keywords: nsclc 1st line treatment gemcitabine vinorelbine docetaxel
effect of iron-fortified pea powder on exercise performance

Conditions: Iron-deficiency

Summary: female endurance athletes are susceptible to iron deficiency and this can impact their exercise performance. this study assesses the impact of an pea protein supplement with high iron bio-availability on iron status and exercise performance.

female endurance athletes are susceptible to iron deficiency due to poor iron intake from diets or possibly because of destruction of red blood cells during foot-strike hemolysis. this study will evaluate the impact of 8-weeks of iron supplementation through consumption of a pea-protein power that has high iron bio-availability due to low phytate levels. this will be compared to consumption of regular iron protein powder and maltodextrin placebo by randomizing participants to three groups. participants will be assessed at baseline and after 8 weeks of supplementation for exercise performance (maximal aerobic capacity and a 5 km time trial running test), blood levels of ferritin and hemoglobin, and body composition (fat mass and lean tissue mass).

Eligibility criteria:
inclusion criteria: * female * regularly participate in aerobic endurance training exclusion criteria: * any contra-indications to exercise testing as determined with the "get active questionnaire"